Researchers found that NLR before treatment was significantly associated with overall survival and progression-free survival.
A retrospective analysis supports the administration of flu vaccination in patients with lung cancer on ICI therapy.
Researchers found that IMP2, a cancer autoantibody, was significantly associated with time to progression in patients with NSCLC treatment with non-frontline PD-1/PD-L1.
Researched conducted a post hoc pooled analysis of 3 KEYNOTE cohorts and found the addition of pembrolizumab improved OS and PFS in patients with NSCLC.
PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.
Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).
A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).